Using Smokeless Tobacco Products With Lower Nicotine Levels to Reduce Negative Effects of Smokeless Tobacco Use
Completed · Phase 1/Phase 2
Conditions studied: Tobacco Use Disorder
In brief
Though spit tobacco is smokeless, it still affects the cardiovascular system and may be associated with heart disease, stroke, and high blood pressure. This study will assess the effectiveness of limiting smokeless tobacco (ST) nicotine intake in reducing levels of exposure to tobacco and associated toxicity, as well as enhancing motivation to either quit or sustain lower levels of nicotine intake.
Key facts
- Study ID
- NCT00218244
- Run by
- National Institute on Drug Abuse (NIDA)
- People needed
- 56
- Starts
- 2001-08-01
- Expected to finish
- 2004-11-01
- Last updated by the study team
- 2017-01-10
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Not interested in quitting ST use within 90 days of study entry
- Has been using ST at least six times a day for 6 months prior to study entry
- Agrees to use an effective form of contraception throughout the study
You may not qualify if…
- Current use of other tobacco or nicotine products
- Pregnant or breastfeeding
- Any unstable medical condition
- Use of any medication that may affect tobacco use or be affected by reduction of tobacco use
- DSM-IV diagnosis of any psychiatric disorders or substance abuse disorders within 6 months prior to study entry
- Use of any psychotropic medications within 6 months prior to study entry
Where it is running
- University of Minnesota — Minneapolis, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.